Wu, Wendy Yi-YingHaider, ZahraFeng, XiaoshuangHeath, Alicia KTjønneland, AnneAgudo, AntonioMasala, GiovannaRobbins, Hilary AHuerta, Jose-MariaGuevara, MarcelaSchulze, Matthias BRodriguez-Barranco, MiguelVineis, PaoloTumino, RosarioKaaks, RudolfFortner, Renée TSieri, SabinaPanico, SalvatoreNøst, Therese HaugdahlSandanger, Torkjel MBraaten, TonjeJohansson, MattiasMelin, BeatriceJohansson, Mikael2023-05-032023-05-032022-10-05Wu WY, Haider Z, Feng X, Heath AK, Tjønneland A, Agudo A, et al. Assessment of the EarlyCDT-Lung test as an early biomarker of lung cancer in ever-smokers: A retrospective nested case-control study in two prospective cohorts. Int J Cancer. 2023 May 1;152(9):2002-2010.http://hdl.handle.net/10668/22117The EarlyCDT-Lung test is a blood-based autoantibody assay intended to identify high-risk individuals for low-dose computed tomography lung cancer screening. However, there is a paucity of evidence on the performance of the EarlyCDT-Lung test in ever-smokers. We conducted a nested case-control study within two prospective cohorts to evaluate the risk-discriminatory performance of the EarlyCDT-Lung test using prediagnostic blood samples from 154 future lung cancer cases and 154 matched controls. Cases were selected from those who had ever smoked and had a prediagnostic blood sampleenAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/EarlyCDT-Lung testbiomarkerslung cancerprediagnostic samplesHumansLung NeoplasmsCase-Control StudiesRetrospective StudiesEarly Detection of CancerSmokersProspective StudiesBiomarkersLungresearch article36305647open accessBiomarcadoresDetección precoz del cáncerEstudios prospectivosEstudios retrospectivosEstudios de casos y controlesFumadoresHumanosNeoplasias pulmonaresPulmón10.1002/ijc.343401097-0215https://doi.org/10.1002/ijc.34340